Company intelligence / Profile preview

JIMRO

Ownership: Private
Employees: ~138
Development stage: Other

Overview

JIMRO has developed innovative medical devices including the GMA system for sepsis/septic shock and the Cilostazol eluting stent system for coronary artery disease. The company has sponsored multiple clinical trials, including multi-center studies on sepsis therapies and exploratory trials of drug-eluting stents. Published literature supports efficacy in modulating immune response via apheresis.

Therapeutic areas: CardiovascularInfectious Diseases
Modalities: DeviceMedical device-based therapy (e.g., apheresis systems, stents)
Industry: Therapeutic Medical Devices

Partnerships

Some academic collaborations inferred from published research

Beyond the preview

Go deeper on JIMRO.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JIMRO.

Explore the full profile